CCR5 and plasma cell myeloma: Two chemokine receptor antagonists have nowbeen approved by the FDA: the CCR5 antagonist maraviroc (Pfizer) fortreatment of HIV/AIDS in patients with CCR5‐using strains; and the CXCR4 antagonistplerixafor (Sanofi) forhematopoietic stem cell mobilization with G‐CSF(CSF3, P09919) in patients undergoingtransplantation in the context of chemotherapy for lymphoma and multiple myeloma.